19.01.2015 • News • Fine Chemicals & Specialty Chemicals • Clariant • Mergers & Acquisitions (M&A)

Clariant Completes Acquisition of Aerochem

Swiss specialty chemicals producer Clariant has completed its acquisition of de-icing chemicals producer Aerochem, based at Stockholm, Sweden, for an undisclosed sum.

The Swedish firm, which claims to have a leading market position in supplying de-icing fluids to the aviation and railway industries in Sweden, Norway and Denmark, has annual sales of around 20 million Swiss francs.

Since 2008, Aerochem has been Clariant's exclusive partner for selling aircraft de-icing fluids to customers in the Nordic market.

Clariant will integrate the acquisition into its business unit Industrial & Consumer Specialties, which claims a leading position in the aviation industry in Europe and North America.

"The acquisition is in line with our growth and sustainability strategy," said Hariolf Kottmann, CEO of Clariant. "Aerochem offers access to the attractive de-icing markets in the Nordics and provides an excellent platform for our activities in recycling of aircraft de-icing fluids in Europe."

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.